Wells Fargo & Company Lowers Repligen (NASDAQ:RGEN) Price Target to $180.00

Posted by Defense World Staff on Feb 27th, 2026

Repligen (NASDAQ:RGEN – Get Free Report) had its price target lowered by research analysts at Wells Fargo & Company from $190.00 to $180.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price target would indicate a potential upside of 34.68% from the company’s current price.

Several other analysts have also recently weighed in on RGEN. Weiss Ratings upgraded shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, February 17th. Barclays raised their target price on shares of Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. UBS Group boosted their price target on shares of Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Jefferies Financial Group set a $160.00 price target on shares of Repligen and gave the stock a “hold” rating in a research note on Tuesday, October 28th. Finally, Wall Street Zen upgraded shares of Repligen from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.58.

Get Our Latest Stock Report on RGEN

Repligen Stock Up 1.1%

Shares of NASDAQ:RGEN opened at $133.65 on Wednesday. The stock’s 50-day moving average is $154.86 and its 200 day moving average is $146.68. The company has a market cap of $7.52 billion, a PE ratio of 157.24, a P/E/G ratio of 2.50 and a beta of 1.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.14. Repligen has a 1 year low of $102.96 and a 1 year high of $175.77.

Repligen (NASDAQ:RGEN – Get Free Report) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.05. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The business had revenue of $197.91 million during the quarter, compared to analysts’ expectations of $192.23 million. During the same quarter last year, the business posted $0.44 EPS. The business’s revenue was up 18.1% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Sell-side analysts anticipate that Repligen will post 1.72 EPS for the current year.

Insider Buying and Selling

In related news, Director Karen A. Dawes sold 275 shares of the business’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total transaction of $44,275.00. Following the sale, the director owned 91,821 shares of the company’s stock, valued at $14,783,181. The trade was a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Repligen

Large investors have recently made changes to their positions in the business. AQR Capital Management LLC purchased a new stake in shares of Repligen in the 1st quarter worth approximately $262,000. Jones Financial Companies Lllp boosted its holdings in Repligen by 3,850.6% in the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock worth $814,000 after acquiring an additional 6,238 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Repligen by 16.8% in the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock worth $18,067,000 after acquiring an additional 20,375 shares in the last quarter. AlphaQuest LLC purchased a new stake in shares of Repligen in the second quarter worth $104,000. Finally, State of New Jersey Common Pension Fund D increased its holdings in shares of Repligen by 1.8% during the second quarter. State of New Jersey Common Pension Fund D now owns 18,252 shares of the biotechnology company’s stock valued at $2,270,000 after acquiring an additional 326 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Repligen

Here are the key news stories impacting Repligen this week:

Positive Sentiment: Q4 beat: Repligen topped Q4 EPS estimates and reported revenue up ~18% Y/Y with solid organic growth and improving margins — the core reason for the bullish reaction. Repligen’s Q4 Earnings Beat Estimates, Revenues Surge Y/Y
Positive Sentiment: Earnings call details/transcript: Management reiterated execution, discussed margin leverage and set FY2026 EPS guidance (1.93–2.01), supporting the beat and forward visibility. Repligen (RGEN) Q4 2025 Earnings Call Transcript
Neutral Sentiment: Analyst nuance: Canaccord maintained a Hold and flagged limited upside at current valuation despite solid execution — suggests investors should watch valuation vs. growth. Repligen: Solid Execution and Credible Growth Outlook, But Upside Limited at Current Valuation
Neutral Sentiment: Narrative shift discussion: Coverage highlights management’s aims on new targets, potential M&A activity and product positioning — strategic developments that could drive longer-term upside but are not immediate earnings catalysts. How The Repligen (RGEN) Narrative Is Shifting With New Targets M&A Plans And Products
Negative Sentiment: Price-target trims: UBS cut its target to $195 (still a buy), Barclays trimmed to $175 (still overweight) and Wells Fargo cut to $180 (still overweight) — modest downgrades to upside expectations that could weigh on near-term momentum. Benzinga TickerReport

About Repligen

(Get Free Report)

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.